Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Scientific Data|August 4, 2023
Proteomic profiling across breast cancer cell lines and modelsMarian Kalocsay, Matthew J Berberich, Robert A Everley, et al.European Journal of Medicinal Chemistry|July 14, 2024
Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7)Wenzhi Ji, Guangyan Du, Jie Jiang, et al.Cell Chemical Biology|November 19, 2019
Development and Characterization of a Wee1 Kinase DegraderZhengnian Li, Benika J Pinch, Calla M Olson, et al.Cell Systems|July 15, 2019
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell LinesMario Niepel, Marc Hafner, Caitlin E Mills, et al.Nature Cell Biology|March 16, 2022
Temporal and spatial topography of cell proliferation in cancerGiorgio Gaglia, Sheheryar Kabraji, Danae Rammos, et al.Cancer Research|January 30, 2021
Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient CellsAnniina Färkkilä, Alfredo Rodríguez, Jaana Oikkonen, et al.Cell Chemical Biology|March 26, 2019
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle PhenotypeCalla M Olson, Yanke Liang, Alan Leggett, et al.Cell Reports. Medicine|May 7, 2026
A human iPSC-derived sensory neuron platform for high-throughput discovery of neuroprotectants against chemotherapy-induced peripheral neuropathyVeselina Petrova, Caitlin E Mills, Clemens Hug, et al.Cancer Research|December 29, 2019
Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor ActivityJohannes C Melms, Sreeram Vallabhaneni, Caitlin E Mills, et al.Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.Pageof 3